CN115768415A - 新型冠状病毒感染症(covid-19)的治疗和/或预防剂 - Google Patents

新型冠状病毒感染症(covid-19)的治疗和/或预防剂 Download PDF

Info

Publication number
CN115768415A
CN115768415A CN202180029760.3A CN202180029760A CN115768415A CN 115768415 A CN115768415 A CN 115768415A CN 202180029760 A CN202180029760 A CN 202180029760A CN 115768415 A CN115768415 A CN 115768415A
Authority
CN
China
Prior art keywords
covid
coronavirus infection
ala
prophylactic agent
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180029760.3A
Other languages
English (en)
Chinese (zh)
Inventor
北洁
森田公一
安田二朗
樱井康晃
河田聪史
田中徹
富冈基康
藤根清考
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newao Pharmaceutical Co ltd
Nagasaki University NUC
Original Assignee
Newao Pharmaceutical Co ltd
Nagasaki University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newao Pharmaceutical Co ltd, Nagasaki University NUC filed Critical Newao Pharmaceutical Co ltd
Publication of CN115768415A publication Critical patent/CN115768415A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180029760.3A 2020-04-22 2021-04-22 新型冠状病毒感染症(covid-19)的治疗和/或预防剂 Pending CN115768415A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020076370 2020-04-22
JP2020-076370 2020-04-22
JP2020-174820 2020-10-16
JP2020174820 2020-10-16
PCT/JP2021/016372 WO2021215517A1 (ja) 2020-04-22 2021-04-22 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の治療及び／又は予防剤

Publications (1)

Publication Number Publication Date
CN115768415A true CN115768415A (zh) 2023-03-07

Family

ID=78269312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029760.3A Pending CN115768415A (zh) 2020-04-22 2021-04-22 新型冠状病毒感染症(covid-19)的治疗和/或预防剂

Country Status (5)

Country Link
US (1) US20230190690A1 (https=)
EP (1) EP4140479A4 (https=)
JP (2) JPWO2021215517A1 (https=)
CN (1) CN115768415A (https=)
WO (1) WO2021215517A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240189269A1 (en) * 2021-03-26 2024-06-13 Tokyo Institute Of Technology Pharmaceutical composition for suppressing tmprss2 expression
WO2024210119A1 (ja) * 2023-04-03 2024-10-10 国立大学法人 長崎大学 化学感覚障害の予防又は治療用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487067A (zh) * 2012-07-19 2015-04-01 思佰益药业股份有限公司 流行性感冒病毒感染症的预防·治疗剂
CN107405323A (zh) * 2015-04-10 2017-11-28 思佰益药业股份有限公司 含有ala类的病毒感染症预防/治疗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5895786A (en) * 1996-05-08 1999-04-20 New York Blood Center, Inc. Method for treating viral infections
EP1591117A4 (en) 2003-02-04 2006-04-26 Yakult Honsha Kk BCRP (BREAST CANCER RESISTANCE PROTEIN) INHIBITOR
US20060135445A1 (en) 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
NZ562143A (en) 2005-03-30 2010-12-24 Yakult Honsha Kk Dimethoxyphenyl-acrylonitrile derivatives and uses thereof in the treatment of cancer
KR20100100826A (ko) 2007-12-03 2010-09-15 가부시끼가이샤 야구르트혼샤 Ａｂｃｇ2 저해제
MX2015016326A (es) 2013-06-18 2016-03-03 Nestec Sa Unidad de filtro para una capsula.
JPWO2020218577A1 (https=) * 2019-04-26 2020-10-29
US10987329B1 (en) 2020-04-22 2021-04-27 Nadimpally Satyavarahala Raju Combination therapy for coronavirus infections including the novel corona virus (COVID-19)
US11883376B2 (en) 2020-04-22 2024-01-30 Nadimpally Satyavarahala Raju Viral infection treatment with 5-aminolevulinic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487067A (zh) * 2012-07-19 2015-04-01 思佰益药业股份有限公司 流行性感冒病毒感染症的预防·治疗剂
CN107405323A (zh) * 2015-04-10 2017-11-28 思佰益药业股份有限公司 含有ala类的病毒感染症预防/治疗剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"NCT04542850", pages 1 - 21, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04542850?tab=history&a=1#version-content-panel> *

Also Published As

Publication number Publication date
WO2021215517A1 (ja) 2021-10-28
JPWO2021215517A1 (https=) 2021-10-28
JP2022008060A (ja) 2022-01-13
EP4140479A4 (en) 2024-05-29
EP4140479A1 (en) 2023-03-01
JP7058026B2 (ja) 2022-04-21
US20230190690A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP5795714B2 (ja) アレナウイルス感染症の治療のための抗ウイルス薬
US20170259081A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
CN104487067B (zh) 流行性感冒病毒感染症的预防·治疗剂
JP2002540156A (ja) 抗ウイルス治療用チアジアゾリルウレアまたはチオウレア誘導体
CN102046180A (zh) 用于免疫治疗的组合物和方法
CN112870367B (zh) Ezh2抑制剂、cdk4/6抑制剂和mek抑制剂在制备治疗肿瘤药物中的用途
TW201912153A (zh) 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
CN115768415A (zh) 新型冠状病毒感染症(covid-19)的治疗和/或预防剂
TWI835050B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
US20230263800A1 (en) Compositions and methods to promote thymic function
US20230263748A1 (en) Application of benflumetol and derivatives thereof in treatment of coronavirus infection
EP4467140A1 (en) Pharmaceutical combination for treating tumors and use thereof
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
JP2005511721A (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
CN115916178A (zh) 非洲猪瘟(African Swine Fever:ASF)的治疗剂和/或预防剂
CN112870366A (zh) Ezh2抑制剂在制备治疗肿瘤药物中的新用途
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
TW201000098A (en) Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for the treatment of severe malaria
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
AU2016277929B2 (en) Combination therapy using belinostat and pralatrexate to treat lymphoma
CN104398517A (zh) 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
CN115089582B (zh) 阿昔替尼在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN115089592B (zh) 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CA2501717C (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
US11786530B2 (en) Method against severe acute respiratory syndrome coronavirus 2 infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination